Liu Xi-De, Zhang Jin-Lu, Zheng Han-Guang, Liu Feng-Yun, Chen Ying
Department of Arthropathy, Zhejiang Provincial Hospital of Integrated Chinese and Western Medicine, Hangzhou 310003, China.
Zhen Ci Yan Jiu. 2008 Jun;33(3):197-200.
To observe the clinical effect of bee-sting (venom) therapy in the treatment of rheumatoid arthritis (RA).
One hundred RA patients were randomly divided into medication (control) group and bee-venom group, with 50 cases in each. Patients of control group were treated with oral administration of Methotrexate (MTX, 7.5 mg/w), Sulfasalazine (0.5 g,t. i.d.), Meloxicam (Mobic,7. 5 mg, b. i. d.); and those of bee-venom group treated with Bee-sting of Ashi-points and the above-mentioned Western medicines. Ashi-points were selected according to the position of RA and used as the main acupoints, supplemented with other acupoints according to syndrome differentiation. The treatment was given once every other day and all the treatments lasted for 3 months.
Compared with pre-treatment, scores of joint swelling degree, joint activity, pain, and pressing pain, joint-swelling number, grasp force, 15 m-walking duration, morning stiff duration in bee-venom group and medication group were improved significantly (P<0.05, 0.01). Comparison between two groups showed that after the therapy, scores of joint swelling, pain and pressing pain, joint-swelling number and morning stiff duration, and the doses of the administered MTX and Mobic in bee-venom group were all significantly lower than those in medication group (P<0.05, 0.01); whereas the grasp force in been-venom group was markedly higher than that in medication group (P<0.05). In addition, the relapse rate of bee-venom group was obviously lower than that of medication group (P<0.05; 12% vs 32%).
Combined application of bee-venom therapy and medication is superior to simple use of medication in relieving RA, and when bee-sting therapy used, the commonly-taken doses of western medicines may be reduced, and the relapse rate gets lower.
观察蜂针(毒液)疗法治疗类风湿关节炎(RA)的临床疗效。
将100例RA患者随机分为药物(对照)组和蜂毒组,每组50例。对照组患者口服甲氨蝶呤(MTX,7.5mg/周)、柳氮磺胺吡啶(0.5g,每日3次)、美洛昔康(莫比可,7.5mg,每日2次);蜂毒组采用阿是穴蜂针治疗并联合上述西药。根据RA病变部位选取阿是穴作为主穴,再根据辨证辅以其他穴位。治疗隔日1次,共治疗3个月。
与治疗前比较,蜂毒组和药物组的关节肿胀度、关节活动度、疼痛、压痛评分,关节肿胀个数、握力、15m行走时间、晨僵时间均有显著改善(P<0.05,0.01)。两组比较,治疗后蜂毒组的关节肿胀、疼痛及压痛评分、关节肿胀个数及晨僵时间,以及所服用的MTX和美洛昔康剂量均显著低于药物组(P<0.05,0.01);而蜂毒组的握力显著高于药物组(P<0.05)。此外,蜂毒组的复发率明显低于药物组(P<0.05;12%对32%)。
蜂毒疗法联合药物治疗在缓解RA方面优于单纯药物治疗,采用蜂针疗法时可减少常用西药剂量,且复发率更低。